J&J | JNJ - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Abbott USD 1.85B 399M 2026-03
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Baxter International USD 66M 280.2M 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Becton, Dickinson and Co. USD 627M 36M 2026-03
Biogen USD 514.3M 128.8M 2026-03
Boston Scientific USD 1.05B 190M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
CONMED USD 25.42M 11.21M 2026-03
Cooper Companies USD -31M 243.8M 2026-03
Dexcom USD 255.3M 67.7M 2026-03
Edwards Lifesciences USD 514.7M 144.4M 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Globus Medical USD 164M 17.31M 2026-03
Insulet USD 122M 24.3M 2026-03
Integra LifeSciences USD 11.47M 54.54M 2026-03
Intuitive Surgical USD 859.7M 5.6M 2026-03
J&J USD 6.62B 1.03B 2026-03
Medtronic USD 2.09B 354M 2026-03
Merck USD -1.88B 8.12B 2026-03
Merit Medical Systems USD 44.16M 10.04M 2026-03
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
Stryker USD 1.1B 867M 2026-03
Tandem Diabetes Care USD 8.29M 31.16M 2025-12
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Zimmer Biomet Holdings USD 395.1M 92.2M 2026-03
Zoetis USD 865M 30M 2026-03